MedPath

High Protein Diet Versus Normal Protein Diet in Treating Patients With Minimal Hepatic Encephalopathy

Not Applicable
Terminated
Conditions
Liver Cirrhosis
Interventions
Dietary Supplement: Normal protein
Dietary Supplement: High protein diet
Registration Number
NCT02418039
Lead Sponsor
Coordinación de Investigación en Salud, Mexico
Brief Summary

A total of 80 patients diagnosed with liver cirrhosis and minimal hepatic encephalopathy will be recruited. They will be randomized to receive high protein diet ( n = 40) and a normal protein diet ( n = 40 ) during one month. Randomization will be conducted by an external monitor and will keep the secret codes until the end of the study. All patients will be provided with structured menus and two snacks a day as an amaranth protein supplement. The supplement will content the same amount of fiber but the protein content will vary depending on the group to which the patient is assigned.

Detailed Description

The protein in the diet is a major source of ammonia in blood, which is considered one of the factors involved in the pathogenesis of hepatic encephalopathy. However ; it is also known than the restriction on the consumption of protein predisposes to depletion of muscle mass, and increase the risk to develop overt hepatic encephalopathy, due to the muscle role in the detoxification of ammonia in presence of liver failure. Currently, the type and amount of protein in the diet to treat minimal hepatic encephalopathy (MHE) is unknown. In this study, the investigators will administrated two types of protein content in patients with MHE: a high protein diet (1.5 g/kg/day) vs a normal protein diet (0.8 g/kg/day) during 1 month.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
42
Inclusion Criteria
  • Diagnosis of cirrhosis of any etiology
  • Men and women between 18 and 70 years.
  • Right-holders of the Mexican Social Security Institute
  • Patients who agree to participate in the study and signed the informed consent
Exclusion Criteria
  • Recent history of alcohol abuse and/or drugs (less than 6 weeks).
  • Illiterate
  • Alcoholic cirrhosis
  • History and/or diagnosis of overt hepatic encephalopathy
  • Consumption of psychotropic medications (benzodiazepines, antiepileptics)
  • Patients under treatment with lactulose, lacitol, rifaximin, neomycin, metronidazole and/or fiber supplements.
  • History of chronic renal disease or heart failure
  • Patients with gastrointestinal bleeding
  • History of neurological or psychiatric disorders that affect the ability to develop neuropsychological tests
  • Diagnosis of bacterial overgrowth
  • Diagnosis of liver cancer
  • Patients with ophthalmologic disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MHE and normal protein dietNormal proteinNormal protein content (0.8 g/kg/day)
MHE and high protein dietHigh protein dietPatients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
Primary Outcome Measures
NameTimeMethod
Reversal of minimal hepatic encephalopathy intervention)1 month

Number of patients who reverts the minimal hepatic encephalopathy after dietary intervention

Secondary Outcome Measures
NameTimeMethod
Nutritional Status1 month

To evaluate the effect of dietary intervention on nutritional status. The nutritional status will be evaluated with the hand strength measured by a dynamometer. A value less than 30 kg will be consider as risk of malnutrition.

Incidence of hepatic encephalopathy1 month

Number of patients that develop minimal hepatic encephalopathy after dietary intervention

Trial Locations

Locations (1)

Instituto Mexicano del Seguro Social

🇲🇽

Mexico, Distrito Federal, Mexico

© Copyright 2025. All Rights Reserved by MedPath